American Journal of Cardiology
Volume 104, Issue 4 , Pages 459-463 , 15 August 2009

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

  • Ole Faergeman, MD, DMSc

      Affiliations

    • Department of Medicine and Cardiology A, Århus University Hospital, Århus, Denmark
    • Corresponding Author InformationCorresponding author: Tel: 45-7527-9072; Fax: 45-7527-9072
    • ,
  • Ingar Holme, PhD

      Affiliations

    • Center of Preventive Medicine, Ullevål University Hospital, Oslo, Norway
    • ,
  • Rana Fayyad, PhD

      Affiliations

    • Pfizer, Inc., New York, New York
    • ,
  • Sonal Bhatia, MD

      Affiliations

    • Pfizer, Inc., New York, New York
    • ,
  • Scott M. Grundy, MD, PhD

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • John J.P. Kastelein, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    • ,
  • John C. LaRosa, MD

      Affiliations

    • State University of New York Health Science Center, Brooklyn, New York
    • ,
  • Mogens Lytken Larsen, MD, DMSc

      Affiliations

    • Department of Medicine and Cardiology A, Århus University Hospital, Århus, Denmark
    • ,
  • Christina Lindahl, MD

      Affiliations

    • Pfizer, Sweden, Sollentuna, Sweden
    • ,
  • Anders G. Olsson, MD, PhD

      Affiliations

    • Department of Internal Medicine, Faculty of Health Sciences, University Hospital, Linköping, Sweden
    • ,
  • Matti J. Tikkanen, MD, PhD

      Affiliations

    • Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • David D. Waters, MD

      Affiliations

    • San Francisco General Hospital, San Francisco, California
    • ,
  • Terje R. Pedersen, MD, PhD

      Affiliations

    • Center of Preventive Medicine, Ullevål University Hospital, Oslo, Norway
    • ,
  • Steering Committees of the IDEAL and TNT Trials

Received 13 January 2009 ,Revised 11 April 2009 ,Accepted 11 April 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The IDEAL and TNT studies were sponsored by Pfizer, Inc., New York, New York.

PII: S0002-9149(09)00910-2

doi: 10.1016/j.amjcard.2009.04.008

American Journal of Cardiology
Volume 104, Issue 4 , Pages 459-463 , 15 August 2009

Article Tools

* Image Usage & Resolution